Drug intelligence / Profile preview

KP8031

Development stage: Preclinical
Lead developer: K Pharma
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Parenteral

Overview

KP8031 is an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy being developed by K Pharma, Inc. for the treatment of chronic cerebral infarction (stroke). The therapy involves the transplantation of neural progenitor cells derived from iPSCs into the brain to promote functional recovery and tissue repair in patients who have entered the chronic phase of stroke. The program is currently in the preclinical research stage and is being developed in collaboration with the Osaka Medical Center. K Pharma is also exploring the expansion of this cell therapy platform into related indications such as chronic cerebral hemorrhage and chronic traumatic brain injury.

Beyond the preview

Go deeper on KP8031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP8031.

Explore the full profile